tirzepatide in the news is fda approved for obesity Breaking News: Approves Treating FDA Approves Diabetes Drug Tirzepatide – FDA says the tirzepatide weight-loss

We still dont know why people with diabetes (and obesity) dont lose as much weight compared with obesity without diabetes (as Drucker and I discussed in the companion podcast)

Safety & interactions Do not share Rybelsus with others, and do not use leftover medication for a new problem

In individuals with T2D and CKD, it is advisable to contemplate the utilization of an SGLT2 inhibitor for additional cardiovascular risk mitigation when the eGFR and UACR levels are at or above 25 mL/min/1.73 m2 or 300 mg/g, respectively

Intestinal microorganisms metabolize TML into trimethyl-5-aminovaleric acid (TMAVA), which can competitively inhibit the binding of -BB to BBD, thereby inhibiting carnitine biosynthesis and FAO in the liver, promoting steatosis and aggravating fatty liver [250]

132: 919923 Griffith OW